Gilead Sciences has set the wholesale price for its new once-a-day HIV/AIDS pill: It’s $28,500 a year. That works out to $78 per pill.
Earlier this year, the Clinton Foundation reported that it has secured generic drugs for delivering combination HIV/AIDS therapy in the developing world for $200 per year. Of course, that requires taking multiple pills several times a day, which makes compliance more difficult.
Gilead’s four-drug combo pill, taken just once a day, clearly is an innovation. But is it really 140 times more valuable than a generic approach? Perhaps the U.S. health care system should sign up for help from the Clinton Foundation.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.